跳到正文
原文
Nature 综合主刊· Zewen Jiang·· 23 天前AI 评分48

小鼠研究:起病窗口期高脂饮食经NLRP3–IL-1β与IL-1R1+ TH17细胞加重皮肤炎症并留下局部免疫记忆

Diet at disease onset determines tissue inflammatory memory

AI 导读

在小鼠IMQ诱导的17型皮肤炎症模型中,与起病重合的4天高脂饮食即可加重炎症,该效应与体重和既存肥胖无关,而同一窗口改用低脂饮食可减轻肥胖小鼠的炎症。机制上高脂饮食先使皮肤中性粒细胞增多,经NLRP3–IL-1β促进IL-1R1+ TH17细胞分化;起病期短暂高脂饮食在皮损消退后仍使再次激发时炎症更重,该记忆局限于曾发炎的皮肤并依赖CD4+组织驻留记忆T细胞。

正文

Main

Obesity alters immune function across multiple contexts, including infection, autoimmunity and cancer7,12,13,14,15,16,17. This effect is especially pronounced in the skin, where obesity exacerbates inflammation and complicates therapeutic responses6,18. Although chronic obesity and weeks to months of obesogenic diet exposure are known to remodel cutaneous immunity, these longer interventions also produce cumulative metabolic, endocrine, microbial and tissue remodelling across multiple organ systems7. It remains unclear whether comparatively brief, days-scale dietary exposures, before such systemic remodelling is established, can acutely modify triggered inflammatory responses and durably imprint long-term tissue inflammatory memory. Experimental models of acute type 17 skin inflammation provide an opportunity to examine these effects, as psoriasis, a type 17 inflammatory disease tightly linked to obesity4,15, has also been associated with dietary patterns and other nutritional exposures19,20,21. We therefore examined whether transient dietary state could bidirectionally modify the response to a synchronized inflammatory trigger, such that HFD amplifies inflammation in lean mice whereas LFD restrains inflammation in obese mice, and whether this acute dietary window could alter subsequent tissue inflammatory recall.

Diet, not body mass, dictates disease

To distinguish the impact of diet itself from the consequences of established obesity, we used topical imiquimod (IMQ) challenge as a synchronized model of acute type 17 skin inflammation in which age-matched mice were fed either a short-term (1 week) or long-term (10 weeks) HFD (60% kcal from fat), or a low-fat (control) diet (LFD; 10% kcal from fat), before topical IMQ challenge22 (Fig. 1a). Mice remained on their assigned diets throughout IMQ challenge. Measurements of serum cytokine levels before application of IMQ did not reveal significant differences between the three groups (Extended Data Fig. 1a), although we did observe modestly increased numbers of TH17 cells and γδ T cells in the skin of mice fed a short- and long-term HFD, relative to the mice fed LFD (Extended Data Fig. 1b–d). Both short- and long-term HFD also reduced glucose tolerance, although these effects were more pronounced in obese mice that were fed a long-term HFD (Extended Data Fig. 2a,b).

Fig. 1: Dietary state, rather than body mass, dictates the magnitude of inflammatory responses in a model of acute type 17 inflammation.

a,f, IMQ model schematics with either HFD (a) or LFD (f) feeding for the indicated durations. b,g, The body weight of mice after HFD (b) or LFD (g) feeding for the indicated durations before IMQ challenge. c,h, The change in ear thickness over the course of disease development in the HFD (c) and LFD (h) groups. d,e,i,j, Representative gross ear images (HFD (d), LFD (i)) and haematoxylin and eosin (H&E)-stained ear sections (HFD (e), LFD (j)) from mice on day 6 of IMQ treatment. w, weeks. k,l, Schematic of 4 days of HFD feeding restricted to 3 days before disease onset and 1 day after disease onset (HFDin) in lean mice (k) and the corresponding change in ear thickness during disease development (l). m,n, Schematic of the 4 days of LFD feeding restricted to 3 days before disease onset and 1 day after disease onset (LFDin) in obese mice (m) and the corresponding change in ear thickness during disease development (n). Scale bars, 100 µm. Data are mean ± s.e.m. n = 10 (b, c, g, h and n) and n = 5 (l) mice per group. Statistical analysis was performed using Brown–Forsythe and Welch’s analysis of variance (ANOVA) followed by Dunnett’s T3 multiple-comparison test (b, c, g, h, l and n). Only peak ear thickness values were used for statistical testing in c, h, l and n. *P < 0.05, **P < 0.01, ***P < 0.001. The diagrams in a, f, k and m were created using BioRender; Jiang, Z. https://BioRender.com/l3wal7h (a), https://BioRender.com/ln9fpc1 (f), https://BioRender.com/6cmulc7 (k), https://BioRender.com/zeduory (m) (2026).

Source data

As expected, 10 weeks of HFD caused marked obesity, whereas HFD for 1 week did not (Fig. 1b). Despite this, both regimens exacerbated IMQ-induced skin inflammation comparably, with approximately 2.1-fold (1 week) and 2.3-fold (10 week) increases in ear thickness relative to the LFD-fed mice (Fig. 1c). Gross examination revealed equivalent levels of ear shortening (Fig. 1d), and histological analysis showed dermal and epidermal expansion in both groups (Fig. 1e). Notably, 1 week of feeding on a medium-fat diet (MFD; 45% kcal from fat) was sufficient to exacerbate disease to a similar extent to the HFD (60% kcal from fat) (Extended Data Fig. 2c,d), indicating that neither extreme fat exposure nor established obesity is required to amplify inflammation. Consistently, western diet (WD; 40 kcal% fat; 29 kcal% sucrose) feeding amplified inflammation after IMQ treatment to the same extent as MFD feeding (Extended Data Fig. 2e). Further, WD or HFD feeding alone did not induce overt ear inflammation or increased ear thickness in the absence of IMQ challenge across the time periods examined (Extended Data Fig. 2f,g), indicating that diet-sensitive amplification of IMQ-induced inflammation is experimentally separable from spontaneous diet-associated dermatitis as reported in some prolonged diet-feeding models23,24.

To determine whether systemic metabolic correction was sufficient to blunt diet-amplified inflammation, we treated HFD-fed mice with semaglutide during the acute dietary exposure and IMQ challenge. Semaglutide was pharmacologically active, improving glucose excursion, reducing body weight, lowering circulating insulin and leptin, increasing GLP-1 immunoreactivity in an assay that recognizes semaglutide, and reducing white adipose tissue mass (Extended Data Fig. 3a–h). However, semaglutide did not broadly reduce baseline inflammatory cytokines, alter gross ear or spleen morphology or substantially remodel splenic conventional T (Tconv) cell subsets (Extended Data Fig. 3i–l). After IMQ challenge, semaglutide did not attenuate HFD-amplified ear thickening or lesional TH17 inflammation (Extended Data Fig. 3m–p). Thus, HFD-conditioned inflammatory susceptibility can persist despite GLP-1 receptor agonist-mediated improvement in systemic metabolic parameters.

IMQ-induced inflammation predominantly stimulates type 17 immune responses, characterized by the production of IL-17A, IL-17F and IL-22 by TH17 cells, γδ T cells and other immune cells22,25. Flow cytometry revealed that acute and chronic HFD similarly increased levels of CD4+ Tconv cells expressing RORγt, the lineage-defining TH17 transcription factor, as well as CD4+ Tconv cells competent for IL-17A, IL-17F and IL-22 in lesional skin and draining lymph nodes (Extended Data Figs. 1b and 4a–d). TH22 cells (IL-17A−IL-22+FOXP3−CD4+ T cells) were also increased, although to a lesser extent than TH17 cells (Extended Data Fig. 4e). CD4+ T cell proliferation (Ki-67+) was increased (Extended Data Fig. 4f), whereas the proportion of Treg cells was reduced under both conditions (Extended Data Fig. 4g). Neutrophils, which are prominent cellular effectors of type 17 inflammation26, were elevated after just 1 week of HFD, mirroring the increase observed with chronic HFD (Extended Data Fig. 4h). By contrast, the proportion of cytokine-producing γδ T cells was unchanged, although total γδ T cell numbers increased in HFD-fed mice (Extended Data Fig. 4i,j).

Finally, we examined whether brief withdrawal of dietary fat could mitigate disease in obese mice. Mice fed HFD for 13 weeks were switched to LFD for 1 week before IMQ challenge, and were compared with obese mice maintained on HFD and with lean LFD-fed control mice (Fig. 1f). Despite persistent obesity (>40 g), the mice that were switched to LFD did not develop the enhanced ear thickness observed in obese mice maintained on HFD (Fig. 1g–j). Thus, dietary state at the onset of inflammation, rather than body mass alone, dictates the magnitude of inflammatory responses after acute challenge with IMQ. This result prompted us to test whether dietary exposure within a specific temporal window is sufficient to drive this effect.

A 4-day diet window sets severity

To define the temporal dynamics of this response, we examined how the timing of HFD feeding influenced IMQ-induced inflammation. Four days of HFD coincident with disease initiation (HFDin) were sufficient to markedly exacerbate inflammation (Fig. 1k,l and Extended Data Fig. 4k,l). Short-term exposure to 15% (w/v) glucose in water during the same peri-initiation window did not enhance IMQ-induced inflammation (Extended Data Fig. 2h–k), suggesting that increased simple sugar exposure is insufficient to recapitulate the acute inflammatory amplification observed with fat-enriched obesogenic diets. By contrast, HFD provided outside this window (HFDout) did not alter disease severity compared with continuous LFD (Extended Data Fig. 2l). Conversely, switching obese mice to LFD during a similar 4-day window (LFDin) protected them from the heightened inflammation observed in obese mice maintained on HFD (Fig. 1m,n), whereas LFD given outside this window (LFDout) offered no protection (Extended Data Fig. 2m). In a complementary experiment, mice that were fed HFD for 1 week and switched to LFD on the day of IMQ initiation (HFDbefore) developed disease severity comparable to mice maintained on HFD, further narrowing the critical dietary window to the onset of inflammation (Extended Data Fig. 2n). Together, these results establish that dietary state during the peri-initiation window, rather than obesity per se, determines disease severity, and raise the question of which immune compartments translate coincident dietary cues into amplified inflammatory responses.

CD4+ T cells mediate HFD exacerbation

We next sought to identify the critical immune cell types that enhance disease severity and type 3 inflammation after HFD feeding. To this end, we first used Rag1−/− mice, which lack adaptive immunity but retain innate lymphoid cells27. These mice were resistant to HFD-induced exacerbation of disease severity, suggesting that adaptive lymphocytes are required for this effect (Fig. 2a,b). Given the known role of γδ T cells as major IL-17 producers in the skin and their significant expansion after long-term HFD feeding18, we examined the effects of short-term HFD on Tcrd−/− mice. Notably, HFD-fed Tcrd−/− mice also developed significantly greater disease compared with LFD-fed controls (Fig. 2c), suggesting that γδ T cells are dispensable for the short-term HFD-induced inflammatory exacerbation. By contrast, HFD-fed Tcra−/− mice, which do not develop αβ T cells, did not develop greater disease compared with their LFD counterparts, suggesting that αβ T cells are required for short-term HFD-induced disease exacerbation (Fig. 2d). To further identify the subset within the αβ T cell compartment required for the HFD-enhanced disease severity, we used B2m−/− mice, which are deficient in CD8+ T cells, and MHCIIΔ/Δ (H2-Ab1, H2-Aa, H2-Eb1, H2-Eb2, H2-Ea null) mice, which lack CD4+ T cells. Notably, only CD4+ T cell deficiency resulted in the loss of the exacerbated disease and inflammatory response caused by HFD in wild-type (WT) mice (Fig. 2e,f). To further confirm the essential role of CD4+ T cells in altering disease trajectory in response to HFD, we treated WT mice with IgG or CD4-depleting antibody. CD4 depletion completely abolished the diet-induced difference in disease severity between mice fed LFD and those fed HFD (Extended Data Fig. 5a–d). Notably, in this setting, LFD-fed mice displayed modest ear thickening accompanied by an increase in cutaneous γδ T cells (Extended Data Fig. 5e). We then sought to identify whether the presence of CD4+ T cells, in the absence of other adaptive immune cells, could produce an exaggerated immune response to HFD. We adoptively transferred bulk CD4+ T cells isolated from the spleen of WT mice into Rag1−/− mice and, after homeostatic expansion, provided HFD or LFD for 1 week, followed by IMQ treatment (Fig. 2g). Rag1−/− mice that were transferred with CD4+ T cells had a robust enhancement of IMQ-induced disease after HFD feeding, with elevated numbers of TH17 cells in the skin (Fig. 2h–k). Taken together, these results demonstrate that CD4+ T cells are critical immunological mediators in translating dietary influences into enhanced inflammatory responses in this model of skin inflammation.

Fig. 2: Exaggerated inflammatory disease severity induced by short-term HFD feeding is mediated by IL-1R1+ TH17 cells.

a–f, The change in ear thickness in WT (a), Rag1−/− (b), Tcrd−/− (c), Tcra−/− (d), B2m−/− (e) and MHCII∆/∆ (f) mice fed LFD or HFD for 1 week and challenged with IMQ. g–k, Bulk CD4+ T cell adoptive transfer into Rag1−/− recipients followed by dietary manipulation and IMQ challenge. g, Experimental schematic. h, The change in ear thickness in adoptive transfer recipients that were fed LFD or HFD. i, The total number of IL-17A+, IL-17F+ and IL-22+ CD4+ Tconv cells in lesional skin. j, Representative flow cytometry plots showing FOXP3 and RORγt expression in CD4+ T cells from lesional skin. k, Quantification of FOXP3+ and RORγt+CD4+ T cell frequencies corresponding to j. l, UMAP visualization with Leiden clustering of scRNA-seq data from lesional CD4+ T cells isolated from LFD- or HFD-fed WT mice after 6 days of IMQ treatment. Treg, regulatory T cells. m, Il1r1 expression overlaid on the UMAP in l; darker shading indicates higher expression. n, The change in ear thickness in Cd4cre mice or T cell-specific Il1r1-deficient (Cd4creIl1r1fl/fl) mice that were fed LFD or HFD for 1 week and challenged with IMQ. Data are mean ± s.e.m. n = 5 (a); n = 10 (b); n = 4 (LFD) and n = 5 (HFD) (c); n = 8 (d); n = 5 (LFD) and n = 6 (HFD) (e); n = 7 (f); n = 6 (h, i and k); n = 1 (pooled from 10 mice per group) for scRNA-seq (l and m); n = 5 (LFD, Cd4cre), n = 5 (HFD, Cd4cre), n = 8 (LFD, Cd4creIl1r1fl/fl) and n = 9 (HFD, Cd4creIl1r1fl/fl) (n). Statistical analysis was performed using two-sided Welch’s t-tests (a–f, h, k and n) and two-sided Mann–Whitney U-tests (i). For i and k, P values were corrected for multiple comparisons using the Holm–Šídák method. Only peak ear thickness values were tested in a–f, h and n. *P < 0.05, **P < 0.01, ***P < 0.001. The diagram in g was created using BioRender; Jiang, Z. https://BioRender.com/t2usnif (2026).

Source data

IL-1R1+ TH17 cells drive HFD effects

To further elucidate the mechanism by which short-term HFD feeding influences CD4+ T cells, we systematically profiled the lesional CD4+ T cells from LFD- and HFD-fed mice after IMQ challenge using single-cell RNA sequencing (scRNA-seq). Exploratory analysis revealed two Tconv cell clusters (TH1 and TH17), four distinct Treg cell clusters (proliferating, resident, central and Penk+)28 and a naive cluster (Fig. 2l). The gene-expression heat maps of effector cytokines (Il17a, Il17f, Il22, Ifng and Fasl)29, key transcription factors (Rorc, Tbx21, Foxp3 and Ikzf2)10,30,31, cytokine receptors (Il23r, Il1rl1, Il1r1 and Il2ra)30, markers of proliferation (Mki67, Cdca3, Spc24 and Pclaf), prominent markers of activation, quiescence, tissue residency and memory (Ccr7, Sell, Itgae, Klf2 and Bcl2)6 and Penk28 validated these population assignments (Extended Data Fig. 5f).

Cells from mice that were fed HFD showed marked differences in distribution across the cell populations, particularly in the TH17 cluster (Extended Data Fig. 6a). In TH17 cells, TH17 effector genes such as Il17a, Il17f, Il22, Il23r and Rorc were significantly upregulated in CD4+ T cells from HFD-fed mice (Extended Data Fig. 6b). Furthermore, leveraging published gene signatures associated with TH17 pathogenicity9,31, we found that short-term HFD feeding markedly enhances the pathogenicity of TH17 cells in the skin (Extended Data Fig. 6c). We performed differential gene expression analysis (Extended Data Fig. 6d and Supplementary Table 1) and found that Il1r1 was the most strongly upregulated gene from TH17 cells taken from mice fed HFD, as measured by fold change (Fig. 2m and Extended Data Fig. 6d). These findings were further validated by flow cytometry, which confirmed that HFD feeding significantly increases IL-1R1 expression in CD4+ T cells from lesional skin (Extended Data Fig. 6e). IL-1R1 signalling has been shown to be critical for stabilizing and enhancing type 3 inflammation10,32. CD4+ T cells expressing Il1r1 exhibited increased expression of TH17 effector genes, along with a higher TH17 pathogenicity score (Extended Data Fig. 6f,g). TH17 differentiation involves multiple inflammatory cues, of which the circuitry is well defined in vitro but less well understood in vivo33,34. These findings suggest that IL-1R1 has a specific and critical role in driving TH17 differentiation in mice being fed HFD.

To directly test this hypothesis, we subjected mice with T cell-specific ablation of IL-1R1 (Cd4creIl1r1fl/fl) to 1 week of LFD or HFD feeding followed by IMQ challenge. Notably, T cell-specific IL-1R1-deficient mice were completely protected from HFD-induced amplification of IMQ-induced skin inflammation, maintaining disease severity levels similar to LFD-fed controls (Fig. 2n and Extended Data Fig. 6h). We did not observe an increase in TH22 cells in T cell-specific IL-1R1-deficient mice (Extended Data Fig. 6i). Collectively, these results demonstrate that short-term HFD exacerbates IMQ-induced type 17 inflammation through IL-1R1+ TH17 cells in the skin lesion.

NLRP3 drives diet-amplified disease

We next examined the mechanistic basis underlying CD4+ T cell induction during IMQ challenge with short-term HFD-feeding. As IL-1α and IL-1β signal through IL-1R135, we investigated whether HFD feeding combined with IMQ challenge increases their expression in the skin. We performed bulk RNA-seq analysis of whole ear tissues from mice that were fed either LFD or HFD and subsequently challenged with IMQ (Supplementary Table 2). Consistent with our earlier findings (Extended Data Fig. 4a,b), the ears of mice fed HFD exhibited a marked upregulation of type 3 cytokine transcripts, including Il17a and Il17f, alongside genes involved in chemotaxis signalling such as Cxcl2, Cxcl3, Ccl3 and Fpr1 (Fig. 3a and Extended Data Fig. 7a). Although both Il1a and Il1b were upregulated in lesional ear skin from HFD-fed mice, the diet-associated increase was more pronounced for Il1b, which increased approximately 3.9-fold (Extended Data Fig. 7b). This pronounced increase in Il1b coincided with a significant upregulation of Nlrp3 (Fig. 3a and Extended Data Fig. 7b). Gene expression analyses of immune cells sorted from the lesions of 15 humans with psoriasis also revealed expression of NLRP3 and IL1B (with specific enrichment in myeloid cells) (Extended Data Fig. 7m–o).

Fig. 3: NLRP3-dependent inflammasome signalling underlies HFD-induced inflammatory exacerbation.

a, Expression of selected genes from RNA-seq analysis of IMQ-treated ears of LFD- or HFD-fed mice. b, The change in ear thickness for WT or Nlrp3−/− mice fed LFD or HFD. c, Representative images and H&E histology of ears of WT or Nlrp3−/− mice on day 6 of IMQ treatment. d, The total number of IL-17A+, IL-17F+, IL-22+ and RORγt+ skin Tconv cells on day 6 of IMQ treatment for WT or Nlrp3−/− mice. e,f, Representative flow cytometry plots (e) and summary graph (f) of IL-1R1+ TH17 cells after IMQ treatment. g, IL-1β quantification from clarified whole-ear lysates after IMQ treatment for WT or Nlrp3−/− mice fed LFD or HFD. h, Visualization in UMAP space of CD45.2+ cells from the skin after IMQ treatment. cDC1/2, type 1/2 conventional dendritic cells; ILC, innate lymphoid cells; NK, natural killer cells; DETC, dendritic epidermal T cells. i,j, Gene expression of Nlrp3 (i) and Il1b (j). k,l, Neutrophils in skin before (k) and after (l) IMQ treatment. m, Geometric fold change in the indicated cell populations in the skin after short-term HFD exposure and after return to LFD. Mono/Mac, monocytes and macrophages. n, The change in ear thickness in IMQ-treated mice that were fed LFD or HFD and treated with isotype control (IgG) or anti-Ly6G antibody (anti-Ly6G). Scale bars, 100 μm. n = 5 (a, f, k, m and n); n = 10 (b); n = 10 (WT) and n = 5 (Nlrp3−/−) mice (d); n = 5 for all conditions except for LFD Nlrp3−/− mice (n = 4) (g); n = 1 (pooled from 10 mice per group) for scRNA-seq (h–j); and n = 6 (l). Data are mean ± s.e.m. Statistical analysis was performed using two-sided Welch’s t-tests (b, d and n), two-sided Mann–Whitney U-tests (k and l) and two-way ANOVA followed by Šídák’s multiple-comparison test (f and g). Only peak values were tested in b and n. For d, P values were corrected for multiple comparisons using the Holm–Šídák method. *P < 0.05, **P <0.01, ***P < 0.001.

Source data

Assembly of the canonical NLRP3-dependent inflammasome leads to the proteolytic cleavage of pro-caspase-1 into active caspase-1, which subsequently processes pro-IL-1β into its mature, active form2,8. We therefore hypothesized that the NLRP3-dependent inflammasome may be important in driving differentiation of IL-1R1+ TH17 cells in the skin of mice fed HFD during disease development. Consistent with this, genetic ablation of NLRP3 abolished this response: HFD-fed Nlrp3–/– mice did not develop exacerbated disease, in contrast to WT controls (Fig. 3b–d), and Nlrp3 deficiency similarly prevented WD-enhanced inflammation relative to CD (Extended Data Fig. 7c–e). Furthermore, Nlrp3 deficiency prevented the HFD-induced increase in IL-1R1+ TH17 cells and IL-1β protein levels observed in WT mice (Fig. 3e–g). Importantly, Nlrp3 deficiency did not confer metabolic protection after short-term HFD feeding. HFD-fed Nlrp3–/– mice exhibited glucose excursion curves and area under the curve (AUC) values comparable to those of the WT controls (Extended Data Fig. 7f,g), indicating that the attenuation of skin inflammation in Nlrp3–/– mice occurs despite modestly increased glucose intolerance. To independently confirm the role of NLRP3, we topically treated WT mice with MCC950, a selective NLRP3 inhibitor, or vehicle. MCC950 treatment protected against HFD-amplified exacerbation of IMQ-induced inflammation (Extended Data Fig. 7h,i), with marked reductions in lesional TH17 cells and neutrophils (Extended Data Fig. 7j,k). Together, these findings establish NLRP3 as a critical amplifier of inflammation during IMQ challenge under brief HFD feeding.

To identify the cellular source of Nlrp3 and Il1b, we sorted lesional CD45.2+ cells from LFD- or HFD-fed mice after IMQ challenge and performed scRNA-seq (Fig. 3h–j). Clustering revealed diverse myeloid and lymphoid populations, confirmed by cell-type-defining marker expression (Extended Data Fig. 5g). Nlrp3 and Il1b were most strongly expressed in neutrophils (Fig. 3i,j). Quantification showed that neutrophil numbers increased with HFD feeding alone, even without IMQ challenge (Fig. 3k); neutrophils rose further after IMQ challenge (Fig. 3l). Notably, semaglutide did not alter HFD-induced neutrophil accumulation in the skin under the baseline conditions (Extended Data Fig. 3q). Consistent with transcriptional priming of the NLRP3 inflammasome, HFD-fed ear skin before IMQ challenge showed increased expression of Il1b and Nlrp3 (Extended Data Fig. 7l). Thus, short-term HFD establishes a neutrophil-enriched and inflammasome-primed tissue state, whereas IMQ provides the acute inflammatory signal required for productive IL-1β protein accumulation and downstream IL-1R1-dependent TH17 amplification. We next examined how rapidly neutrophil accumulation in skin responds to dietary change. Flow cytometry profiling revealed that neutrophil numbers, but not CD4+ or CD8+ T cells, γδ T cells, B cells or monocytes, showed the largest early increase after short-term HFD feeding and returned to near the baseline 7 days after switching back to the LFD (Fig. 3m). Finally, depletion of neutrophils with anti-Ly6G antibodies abrogated HFD-induced ear thickening during IMQ treatment (Fig. 3n), establishing neutrophils as required mediators of the diet-amplified inflammatory response.

We wondered whether this effect of coincident dietary state extended beyond the skin. To test this, we examined the lung in an experiment in which mice were fed HFD or LFD for 1 week and then challenged intranasally with LPS. We observed a significant increase (around fivefold) in neutrophil counts just after HFD feeding (before LPS treatment) (Extended Data Fig. 8a). After challenge with LPS, HFD-fed mice showed an increased change in lung weight and heightened TH17 inflammation relative to the LFD-fed controls (Extended Data Fig. 8b–d). This response was abolished by neutrophil depletion or T-cell-specific loss of Il1r1 (Extended Data Fig. 8e,f). Thus, coincident dietary state amplifies acute inflammatory responses in a mechanistically similar manner across tissues, indicating that this effect is not skin restricted.

HFD at onset amplifies recurrence

Psoriasis is a chronic inflammatory disease characterized by onset, recovery and repeated recurrence36. Inflammatory memory is increasingly recognized as a tissue-retained property that may facilitate relapse at sites of previous inflammation11,37,38. To test whether diet over disease onset (DODO) shapes disease trajectory beyond the initial flare, we developed an IMQ-induced inflammation recurrence model (Fig. 4a). Mice were placed on LFD or HFD for 1 week, then subjected to daily IMQ challenge for 6 days while continuing the assigned diet. As expected, the HFD-fed mice exhibited roughly twofold greater ear thickening compared with the LFD-fed control mice during the acute phase. Thereafter, all mice were returned to LFD and IMQ treatment was discontinued. After approximately 25 days of recovery, both groups appeared fully resolved by gross examination, ear thickness measurement, histology, bulk RNA-seq and serum cytokine profiling (Fig. 4b,c and Extended Data Fig. 9a–d).

Fig. 4: Transient HFD at disease onset establishes durable, tissue-localized inflammatory memory.

a, Schematic of the IMQ-induced skin inflammation recurrence model. b, Change in ear thickness during the initial flare, recovery phase and second flare in the LFD and HFDDODO cohorts. c, Representative gross ear images and H&E-stained sections at the end of recovery and after the second flare. d–f, Immune profiling after the second flare. d, Numbers of lesional Tconv cells expressing IL-17A, IL-17F, IL-22 or RORγt. e, The total number of neutrophils in lesional skin. f, The mean fluorescence intensity (MFI) of IL-1R1 on Tconv and Treg cells. g, Quantification of CD4+ TRM cells in previously inflamed (left) and previously unchallenged (right) ears during recovery. h, Illustrative thick-slice imaging of recovered skin showing CD4+ T cells (red) in LFD and HFDDODO mice. Imaging was performed in two mice per group, with three sections examined per mouse. i–k, UMAP visualization of snATAC–seq profiles from sorted CD4+ T cells of recovered skin showing cluster structure (i) and condition-specific enrichment (j) with genome browser tracks (k) at the Il1r1 and Il23r loci (promoter regions in green; putative regulatory elements in yellow). l, Schematic of CD4+ T cell depletion. m, Change in ear thickness during the second flare in mice treated with isotype control (IgG) or anti-CD4. n, Schematic of full-thickness skin transplantation (Tx) from recovered donors. o, Representative gross images of grafted skin after IMQ challenge. p, Representative H&E-stained sections of grafted skin after IMQ challenge. Scale bars, 100 µm (c, h (left) and p) and 20 µm (h, right). n = 5 (b, f, g and m); n = 10 (d and e); and n = 1 (pooled from 20 mice per group) for snATAC–seq (i–k). Data are mean ± s.e.m. Statistical analysis was performed using two-sided Welch’s t-tests (b, d, e and m) and two-way ANOVA followed by Šídák’s multiple-comparison test (f and g). For d, P values were corrected using the Holm–Šídák method. Only peak values were tested in b and m. *P < 0.05, **P < 0.01, ***P < 0.001. The diagrams in a, g, l and n were created using BioRender; Jiang, Z. https://BioRender.com/rr7rsxf (a), https://BioRender.com/ht8s5kb (g), https://BioRender.com/bwofnm2 (l), https://BioRender.com/jm782f8 (n) (2026).

Source data

On secondary IMQ challenge, however, HFDDODO mice developed a markedly more rapid and severe disease recurrence, with around twofold greater ear thickening, elevated TH17 cell numbers, enhanced neutrophil accumulation and sustained IL-1R1 expression in conventional CD4+ T cells compared with the LFD-fed control mice (Fig. 4b–f). This enhanced response in HFDDODO mice was durable: mice that were allowed to recover for 6.5 months after the initial flare continued to exhibit exaggerated ear thickening after rechallenge (Extended Data Fig. 9e). Importantly, transient HFD in the absence of IMQ did not confer durable effects: such mice responded like the LFD-fed control mice on rechallenge (Extended Data Fig. 9f). Moreover, when mice that had recovered from initial disease were rechallenged, only the previously inflamed ears—not contralateral naive ears—exhibited exaggerated recurrence in HFDDODO animals (Extended Data Fig. 9g), indicating that the long-term immunomodulatory imprint of DODO is localized and tissue specific. We further found that obese mice maintained on HFD at disease onset developed recurrence equivalent to lean mice that were exposed to HFD at disease onset, underscoring that dietary context coincident with the inflammatory trigger, rather than previous obesity or dietary history, dictates the establishment of diet-induced inflammatory memory (Extended Data Fig. 9h–j). In addition, blocking lymphocyte egress with FTY72039 during the second flare did not prevent HFDDODO-induced exaggerated inflammation, further suggesting a tissue-resident immune response (Extended Data Fig. 9k,l).

CD4+ TRM cells mediate dietary memory

We next examined whether skin-resident immune cells mediated these durable effects. To address this, we profiled previously inflamed (left) and unchallenged (right) ears of recovered mice before secondary challenge. In HFDDODO mice, previously inflamed ears contained around 2.3-fold more CD4+ tissue-resident memory (TRM) cells40 compared with LFD-fed controls, whereas unchallenged ears showed no differences (Fig. 4g and Extended Data Fig. 9m). Consistent with the flow cytometry findings, thick-section imaging of back skin 45 days after IMQ withdrawal revealed a greater accumulation of CD4+ T cells (red) in HFDDODO mice (Fig. 4h), concentrated around the hair follicle near the sebaceous gland—a region where follicle-associated immune niches have previously been described41,42. To further resolve the CD4+ T cell compartment, we sorted CD4+ T cells from recovered ears and performed single-nucleus assay for transposase-accessible chromatin (snATAC–seq; Fig. 4i). Dimensionality reduction revealed marked chromatin heterogeneity, including multiple clusters with features consistent with TRM cells (Extended Data Fig. 10a). Notably, one population (cluster 8) was selectively enriched in HFDDODO mice relative to LFD-fed control mice (Fig. 4j). This cluster exhibited increased chromatin accessibility at loci encoding key inflammatory signalling receptors, including Il1r1 and Il23r (Fig. 4k), alongside accessibility at Hlf, a transcription factor that was recently implicated in CD4+ TRM programming43, Il21, Ccl20 and Tnfsf4 (Extended Data Fig. 10b). By contrast, cluster 8 showed reduced accessibility at Ikzf2, a regulator associated with regulatory T cell identity, as well as Tox and Il6st (Extended Data Fig. 10c). Together, these features define cluster 8 as a distinct CD4+ TRM-like population epigenetically poised for IL-1 and IL-23 responsiveness. These findings indicate that transient HFD exposure durably reshapes the chromatin landscape of skin-resident CD4+ T cells, biasing inflammatory recall responses long after dietary normalization.

To formally establish the functional significance of CD4+ T cells in mediating dietary inflammatory memory, we administered CD4-depleting antibodies or isotype controls to recovered mice and then rechallenged them with IMQ (Fig. 4l). HFDDODO mice treated with isotype control antibodies developed exacerbated recurrent disease, whereas anti-CD4 treatment abolished the difference between the HFDDODO and LFD groups (Fig. 4m). Thus, the CD4+ cell compartment is required for the expression of durable inflammatory memory induced by transient HFD feeding. Further supporting this mechanism, topical administration of the NLRP3 inhibitor MCC950 during the initial challenge reduced the exaggerated recurrence observed in HFDDODO mice, whereas identical treatment during recurrence conferred no benefit (Extended Data Fig. 9n). These results indicate that local NLRP3 activation during the initial inflammatory episode is required to establish diet-induced inflammatory memory, which is subsequently mediated by CD4+ T cells.

A defining feature of tissue-resident memory is the persistence of the memory response after transplantation. To test whether diet-induced inflammatory memory was similarly tissue intrinsic, we transplanted previously inflamed back skin from recovered HFDDODO or LFD mice—pretreated with either IgG isotype control or anti-CD4 antibodies—onto naive recipients and subjected them to IMQ challenge (Fig. 4n). Grafts from IgG-treated HFDDODO donors displayed markedly increased pathology compared with the IgG-treated LFD controls, including prominent scaling and surface roughening (Fig. 4o) as well as epidermal thickening and elevated leukocytic infiltration in the dermis (Fig. 4p). Thus, transient HFD exposure during disease onset is sufficient to imprint a CD4+ T-cell-dependent, tissue-intrinsic program that amplifies inflammatory recall responses after recovery.

Discussion

Transient exposure to HFD during a narrowly defined peri-initiation window durably reshapes tissue immunity without requiring obesity. The consequence is not merely heightened acute pathology but a lasting change in local immune responsiveness that becomes evident months later after rechallenge, after return to LFD. These experiments identify dietary state, rather than accumulated adiposity, as the proximate determinant of disease amplification. Three compositionally distinct fat-enriched diets—HFD, MFD and WD—each amplified IMQ-induced type 17 skin inflammation, whereas glucose water alone did not. Conversely, transiently switching persistently obese mice from HFD to LFD during a corresponding four-day peri-initiation window attenuated disease. Semaglutide further sharpened this dissociation: GLP-1 receptor agonism improved glucose handling, reduced body weight and adiposity, and lowered circulating insulin and leptin, but did not attenuate HFD-amplified inflammatory responses. Although longer-term treatment with GLP-1 receptor agonists and related incretin-based therapies may improve established psoriasis in patients with obesity or type 2 diabetes44,45,46,47, our experiment addressed the distinct question of whether short-term semaglutide treatment blocks the additional amplification imposed by coincident HFD exposure. It did not, indicating that systemic metabolic improvement and diet-primed inflammatory susceptibility are separable. Whereas prolonged high-fat or Western-style feeding has previously been shown to exacerbate IMQ-induced and IL-23-driven inflammation48,49,50 and, with sustained exposure, promote spontaneous dermatitis23,24, as little as 4 days at inflammatory onset was sufficient here. HFD alone did not confer durable susceptibility to a later inflammatory challenge, indicating that dietary exposure must intersect with tissue inflammation to imprint the long-term phenotype. Our findings may also help explain a previous observation that leptin-deficient ob/ob mice did not exhibit increased IMQ susceptibility despite profound adiposity49. As leptin supports optimal TH17 differentiation51, its absence may limit engagement of the IL-1β–TH17 axis. Consistent with this possibility, transient peri-initiation HFD amplified IMQ-induced inflammation in WT but not ob/ob mice (Extended Data Fig. 2o).

Mechanistically, the data support a model linking neutrophil-dependent inflammatory signalling to durable tissue immune memory (Extended Data Fig. 10d). Brief HFD increased neutrophil accumulation in skin before overt disease; after inflammatory challenge, Nlrp3 and Il1b were expressed predominantly in neutrophils, and NLRP3–IL-1β signalling licensed IL-1R1+CD4+ T cell responses. NLRP3 inhibition was effective during the initial challenge but not at rechallenge, whereas tissue-resident CD4+ T cells mediated recall, distinguishing memory establishment from memory expression. Skin transplantation further showed that a systemic dietary exposure can be encoded as spatially restricted memory within previously inflamed tissue. How brief HFD drives neutrophil accumulation before overt disease remains unresolved. Targeted lipidomics of skin before IMQ challenge revealed rapid remodelling of the cutaneous lipid environment (Extended Data Fig. 10e), while bulk RNA-seq identified increased expression of genes involved in fatty acid transport, lipid droplet formation and lipid storage (Extended Data Fig. 10f). Although these data do not identify the causal lipid species, receptor or stromal compartment, they nominate local lipid metabolism as an upstream process linking short-lived dietary change to neutrophil accumulation and transcriptional inflammasome priming. This interpretation is consistent with reports of rapid neutrophil recruitment and neutrophil-dependent inflammation after HFD52,53, lipid flux-dependent neutrophil recruitment in adipose tissue54, and FABP-dependent inflammasome and type 17 signalling in skin24,55. The dependence of HFD-amplified LPS-induced lung inflammation on neutrophils and T-cell-intrinsic IL-1R1 signalling suggests that a related acute diet-sensitive mechanism operates beyond skin, although durable inflammatory memory was established here only in skin.

The distinct requirements for memory establishment and recall suggest opportunities for intervention at different stages of disease. Dietary modulation around inflammatory onset may exert disproportionate effects relative to changes during quiescence. Targeting NLRP3 during the initial challenge or interrupting IL-1R1 signalling may prevent the establishment of a maladaptive resident memory program that amplifies recurrence. More broadly, transient physiological states may become embedded in local immune memory when they coincide with tissue inflammation.

Methods

Mice

Mouse studies were conducted at the University of California, San Francisco (UCSF). Mice were housed in specific-pathogen-free facilities in temperature- and humidity-controlled animal facilities, with ambient room temperature maintained between 19 and 23 °C and relative humidity ranging from 40% to 60%. Mice were maintained under a 12 h–12 h light–dark cycle, with lights on from 07:00 to 19:00, and were group-housed with ad libitum access to food and water. When required, mice were purchased from The Jackson Laboratory. By default, mice fed at UCSF were given irradiated PicoLab Rodent Diet 20 5053. For experiments requiring the use of special diets, diets were irradiated and purchased from Research Diets. The HFD was 60 kcal% fat (D12492), and the control LFD was 10 kcal% fat (D12450J). The MFD was 45 kcal% fat (D08091803). The 30 kcal% fat diet was D20072301. The Western diet was D18053102, and the matched control diet was D18053101. Mice designated as obese in this study were fed the HFD for at least 10 weeks, starting at an age of 6–7 weeks, and weighed at least 38 g (as an average within a cage). For short-term HFD feeding, 6-week-old mice were given HFD for 7 days before the IMQ challenge unless otherwise indicated. Unless otherwise indicated, mice remained on their assigned diets throughout IMQ treatment. For HFDin feeding, lean mice were placed on HFD starting 3 days before IMQ challenge and remained on this diet until 1 day after initiation. For LFDin feeding, obese mice were placed on LFD starting 3 days before IMQ challenge and remained on LFD until 1 day after initiation. For HFDout feeding, lean mice were maintained on LFD, except for two distinct periods when they were switched to HFD: first, from 7 to 3 days before IMQ initiation and, later, from 3 to 6 days after initiation during disease progression. For LFDout feeding, obese mice were maintained on HFD, except for two distinct periods when they were switched to LFD: first from 7 to 3 days before IMQ initiation and, later, from 1 to 6 days after initiation during disease progression. For HFDDODO feeding, mice were placed on HFD throughout the entire disease onset phase (spanning 7 days before to 6 days after IMQ initiation) and were then returned to LFD for the recovery and rechallenge phases. C57BL/6J (000664), B6.SJL-Ptprca Pepcb/BoyJ (002014)56, Rag1−/− (002216)57, Tcra−/− (002116)58, B6.129S2-H2dlAb1-Ea/J (MHCIIΔ/Δ) (003584)59, B2m−/− (002087)60, Tcrd−/− (002120)61, Cd4cre (022071)62 and Nlrp3−/− (021302)63 mice were purchased from The Jackson Laboratory. Il1r1fl/fl (ref. 64) and Cd4creERT2Ai14 mice65,66 were provided by the Scharschmidt Lab at UCSF. All of the mice used for the studies were male. All procedures involving animals were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of UCSF.

IMQ-induced acute type 17 skin inflammation model

IMQ-induced acute type 17 skin inflammation was generated in mice at various ages fed with either the LFD or HFD. In brief, mice were anaesthetised using isoflurane, and 15 mg cream containing 5% IMQ (TARO) was topically applied to the dorsal and ventral sides of the mouse ear daily for 6 days (ref. 22). Ear thickness was measured daily with a digital micrometer (Mitutoyo). Then, 24 h after the last application, mice were euthanized, and ears were collected for flow cytometry, RNA extraction, histological analysis and other downstream applications. For rechallenge experiments, after the last day of IMQ treatment during the initial challenge, mice were allowed to recover. Ear thickness was measured weekly to evaluate recovery. Unless otherwise stated, after 25–30 days, mice were subjected to 15 mg cream containing 5% IMQ treatment for 4–6 consecutive days. To inhibit NLRP3 activation, MCC950 sodium (S7809, Selleckchem) was prepared in 50 mg ml−1 in water and 75 μg was given topically to each mouse daily in sync with application of IMQ. For experiments involving dorsal back skin, mice were anaesthetised with isoflurane 1 day before IMQ treatment, and an approximately 2.5-cm2 area was shaved and treated with Nair depilatory cream, which was promptly rinsed off with water. Under isoflurane anaesthesia, 50 mg of cream containing 5% IMQ (TARO) was applied topically to the prepared back skin daily for 6 consecutive days. For rechallenge experiments, shaving and depilation were performed only before the initial challenge and were not repeated before the second IMQ challenge.

Histology of lesional ear skin

Ear skin was collected and submerged in 4% paraformaldehyde (PFA) overnight. Tissues were then embedded, sectioned and stained with H&E by the Histology and Light Microscopy Core at Gladstone Institutes. Images were taken using a Zeiss microscope. The scale bar was added by converting pixels to μm using ImageJ.

Serum cytokine, hormone and IL-1β assays

Serum was collected and submitted to Eve Technologies for quantification using Luminex-based assays. For tissue IL-1β measurements, individual whole ears were collected and processed separately. Each ear was minced in 400 µl lysis buffer at 4 °C and homogenized using a Precellys Cryolys tissue homogenizer. Homogenates were clarified by centrifugation, and 100 µl of clarified lysate from each sample was submitted to Eve Technologies for Luminex-based cytokine quantification. IL-1β concentrations were calculated from standard curves and are reported as pg ml−1 of clarified lysate generated from one whole ear homogenized in a fixed volume of lysis buffer.

Glucose tolerance test

Fasting was induced for 2 h. Glucose (2.0 g kg−1, intraperitoneally) was injected and serum was collected for glucose measurements. Blood glucose was monitored using a Nova Max Plus glucometer.

Semaglutide injections

Mice were administered semaglutide (Selleck Chemicals, S9697) by daily intraperitoneal injection at a dose of 120 µg per kg. Treatment was initiated at the onset of exposure to either HFD or LFD and continued daily until the end of IMQ treatment. Semaglutide was dissolved in a vehicle consisting of PBS:kolliphor:DMSO at a ratio of 18:1:1. Control mice received daily intraperitoneal injections of vehicle alone. Injection volume did not exceed 150 µl per mouse.

Ear immune cell suspensions

Dissected mouse ear skin was separated into dorsal and ventral halves and incubated in 1 ml of digestion buffer. Mouse skins were incubated in 1 ml digestion buffer (RPMI-1640 medium with 2% FCS and 1× penicillin–streptomycin–glutamine solution (10378016, Roche) containing 0.2 mg ml−1 liberase (05401020001, Roche), 0.2 mg ml−1 DNase I (DN25-100MG, Sigma-Aldrich) and 0.5 mg ml−1 hyaluronidase (LS002592, Worthington). After incubation for 30 min, the skin samples were minced into fine pieces (1–2 mm3) and incubated for another 30 min. The suspension was then passed through a 40 μm mesh to remove undigested clumps and debris. The flow-through was centrifuged at 500 rcf for 5 min. The pellet containing the stromal vascular fraction was washed once in 10 ml RPMI, and the resultant isolated cells were prepared for fluorescence-activated cell sorting (FACS) analysis directly or first stimulated with PMA and ionomycin in the presence of brefeldin A (Cell Activation Cocktail; BioLegend) for 1.5 h at 37 °C for subsequent intracellular cytokine staining and then prepared for FACS analysis.

In vivo antibody treatments

The following antibodies were used: anti-mouse CD4 (BioXCell, GK1.5), isotype control for anti-mouse CD4 (rat IgG2b, BioXCell, LTF-2), anti-mouse Ly6G (BioXCell, 1A8) and isotype control for anti-mouse Ly6G (rat IgG2a, BioXCell, 2A3). For the anti-CD4 experiments: antibodies were injected intraperitoneally 2 days before, on the day of, and 2 days after the initiation of the IMQ challenge at a dose of 0.1 mg per mouse. For the rechallenge experiment, anti-CD4 or isotype control antibodies were injected intraperitoneally on days 29, 32 and 35 after the initial IMQ challenge using the same dosage. For the anti-Ly6G experiments: antibodies were injected intraperitoneally 3 days before, 1 day before, 1 day after, 3 days after, and 5 days after the initiation of the IMQ challenge at a dose of 0.1 mg per mouse. Injection volumes never exceeded 150 µl. For the LPS-induced lung inflammation model, antibodies were injected intraperitoneally 3 days before, 1 day before, 1 day after and 3 days after the LPS challenge at a dose of 0.1 mg per mouse. Injection volumes never exceeded 150 µl.

Adoptive transfer of CD4+ T cells

CD4+ T cells were isolated from the spleens of WT mice using the Mouse CD4+ T Cell Isolation Kit (StemCell) and 100,000 cells were transferred intravenously into Rag1−/− mice. After an 8-week reconstitution period, mice were fed LFD or HFD for 1 week. Mice were then subjected to IMQ treatment for 6 days to induce acute type 17 skin inflammation. Disease severity was assessed by ear thickness measurements, and immune responses were analysed by flow cytometry.

Flow cytometry

Fc Block (2.4G2, 553141, BD) was diluted in FACS buffer and added to each sample 5 min before performing surface staining. eBioscience Fixable Viability Dye eFluor780 was used to distinguish live from dying or dead cells. Cell surfaces were stained for 30 min at 4 °C. For intracellular staining, cells were treated with fixation and permeabilization reagents from eBioscience and labelled with the appropriate antibodies before being analysed. Data were analysed using Aurora Cytek (v.4.0.1) and FlowJo software (v.10 and v.11, FlowJo). Cells were sorted on the Cytek Aurora CS System. The following antibodies were used: CD45.2 (104, 109839, BioLegend), CD197 (4B12, 120120, BioLegend), CD11c (N418, 117322, BioLegend), CD11b (M1/70, 101224, BioLegend), CD44 (IM7, 103037, BioLegend), TCRγδ (GL3, 563993, BD), CD62L (MEL-14, 20-0621-U025, TONBO), CD69 (H1.2F3, 104506, BioLegend), Ly6G (1A8, 127672, BioLegend), CD3ε (145-2C11, 100349, BioLegend), CD4 (RM4-5, 100528, BioLegend), CD8α (53-6.7, 100744, BioLegend), Ki-67 (SolA15, 367-5698-82, Invitrogen), RORγt (Q31-378, 562684, BD), FOXP3 (FJK-16s, 46-5773-82, Invitrogen), IL-17A (TC11-18H10.1, 506914, BioLegend), IL-17A (TC11-18H10.1, 506925, BioLegend), IL-17F (9D3.1C8, 517008, BioLegend), CD121a (35F5, 564387, BD), CD121a (JAMA-147, 113505, BioLegend), IFNγ (XMG1.2, 505806, BioLegend), IL-22 (Poly5164, 516409, BioLegend). Antibodies against Fc Block, CD45.2, CD197, CD11c, CD11b, CD44, TCRγδ, CD62L, CD69, Ly6G, CD3ε, CD4 and CD8α were used at a 1:200 dilution; antibodies against Ki-67, RORγt, FOXP3, IL-17A, IL-17F, CD121a (clones 35F5 and JAMA-147), IFNγ and IL-22 were used at a 1:400 dilution. eBioscience Fixable Viability Dye eFluor780 (65-0865-14) was used at a 1:1,000 dilution.

Lesional CD4+ T cell scRNA-seq

CD4+ T cells from mouse ear skin were FACS-sorted, and mRNA isolation, cDNA synthesis and library preparation were then performed based on the protocol provided by PIPseq T2 3′ Single Cell RNA Kit v4.0PLUS (Fluent BioSciences). In brief, cells were sorted by FACS (sorting on live CD45.2+CD3ε+CD4+ cells on a Cytek Aurora CS System) in cell suspension buffer (provided in the kit) with 1 U μl−1 RNase inhibitor. Then, 4 μl cell suspension (5,000 cells maximum) with 20 U of RNase inhibitor was added to each PIP tube reaction, followed by vortexing to generate single bead to cell emulsion. We performed 16 cycles of PCR for cDNA amplification after cDNA synthesis, and 25% of each cDNA sample was carried into transcriptome library preparation. PIPseq T2 3′ Single Cell gene expression libraries were subject to standard Illumina paired-end sequencing targeting 20,000 reads per input cell using the NovaSeq X system.

Raw fastq files were mapped to the mouse transcriptome (UCSC mm10) using PIPseeker67 (Fluent BioSciences, v.3.2) pipeline that performs barcode whitelisting, alignment with STAR, and molecular index correction and generates barcode-feature counts matrices. After alignment and sensitivity calling (sensitivity_5 was chosen for all three samples), 2,103 cells were recovered from the LFD condition and 5,232 cells were recovered from the HFD condition—two T2 PIPseq reactions were used, labelled HFD1 and HFD2. Subsequent analysis was performed using Scanpy (v.1.10.4)68. The three datasets were concatenated into one AnnData object. Low-quality cells (number of genes < 200) and genes (expressed in fewer than three cells) were removed. Doublets were identified and removed using the scrublet function. Data were normalized to 10,000 reads per cell and logarithmized before clustering. Clusters were calculated using the Leiden algorithm and visualized using UMAP. Three clusters (clusters 8, 11 and 12) were excluded due to contamination (monocytes and stromal cells) or high mitochondrial content. Cell types were annotated based on the expression level of known genes and differential gene expression analysis, using the rank_genes_group function. After quality-control filtering (for doublets and non-CD4+ T cell contamination), 1,769 CD4+ T cells remained in the LFD condition, and 4,450 CD4+ T cells remained in the HFD condition, with over 1,500 median genes per cell. To assess TH17 pathogenicity, we calculated a TH17 pathogenicity score based on published gene signatures associated with pathogenic TH17 cells9,31. Gene sets from both studies, comprising key regulators and effector genes that define pathogenic TH17 cells, were curated and used to evaluate the pathogenic potential of TH17 cells in our dataset. Using the score_genes function in Scanpy, we calculated the TH17 pathogenicity score for each cell in the TH17 cluster. To compare differentially expressed genes in TH17 cells in HFD compared to LFD samples, differential gene expression analysis was performed using Scanpy’s rank_gene_groups function, with tie correction for Wilcoxon scores. To remove background noise of genes expressed by few cells, genes expressed in fewer than 100 cells were excluded. Genes with log2[fold change] > 1 and P < 0.0001 were displayed. Plotting was performed using matplotlib (v.3.9.3) and seaborn (v.0.13.2).

Whole-ear bulk RNA-seq

Total RNA was extracted from whole mouse ear skin before, at the end of or 26 days after IMQ challenge using the RNeasy Fibrous Tissue Kit according to the manufacturer’s protocol (74704, Qiagen). RNA quantity and quality were determined by NanoDrop spectrophotometers and Qubit 4 fluorometer. In total, 10 μg RNA from each sample was sent to Genewiz for library preparation and sequencing services (RNA-seq). Read alignment and junction finding were accomplished using STAR69 using UCSC mm10 as the reference sequence. Differential gene analysis and data visualization were performed in R using the DESeq270 package.

Lesional immune-cell scRNA-seq

Single-cell gene expression libraries were generated using the Chromium Single Cell Fixed RNA Profiling (Flex) platform (10x Genomics) according to the manufacturer’s instructions. Fixed single-cell suspensions were encapsulated using the Chromium Controller to generate barcoded gel beads in emulsion, followed by reverse transcription and library construction per the 10x Genomics Flex protocol. Libraries were sequenced on an Illumina NovaSeq X platform to obtain paired-end reads. Resulting raw fastq files were mapped to the reference genome (GRCm39) using the Cell Ranger’s multi pipeline71. Resulting matrix, barcodes and features files were analysed using Scanpy (v.1.10.4). A total of 27,738 cells was analysed (14,990 HFD and 12,748 LFD). The two datasets were concatenated into one AnnData object. Low-quality cells (number of genes < 200) and genes (expressed in fewer than three cells) were removed. Doublets were identified and removed using the scrublet function. Data were normalized to 10,000 reads per cell and logarithmized before clustering. Clusters were calculated using the Leiden algorithm (resolution = 0.5) and visualized using UMAP. Differentially expressed genes were determined using the rank_genes_groups function. Using the PanglaoDB database72 and decoupler’s OmniPath module73, cell type scoring was performed to help assign cell type labels. Using this, together with differentially expressed genes and expression levels of known markers, 17 different cell types were identified. Differentially expressed genes between conditions were calculated using rank_genes_groups. Plotting was performed using matplotlib (v.3.9.3) and seaborn (v.0.13.2).

Recovered-skin CD4+ snATAC–seq

snATAC libraries were prepared using the Chromium Single Cell ATAC v2 kit (10x Genomics) according to the manufacturer’s protocol. Nuclei were isolated, transposed using Tn5 transposase and barcoded by droplet-based partitioning on the Chromium Controller, followed by library amplification and construction. Libraries were sequenced on an Illumina NovaSeq X platform to generate paired-end reads for downstream alignment and peak calling. Resulting raw fastq files were mapped to the reference genome (GRCm39) using Cell Ranger’s atac count pipeline71. Subsequent analysis was performed using ArchR74 (v.1.0.3). In the first step, arrow files were created from the fragment files using the barcodes that passed the cellranger pipeline. Analysis was performed using the mouse GRCm39 genome. After initial quality control, where fragment size distribution, TSS enrichment and number of fragments per cell were visualized, peaks were called using the addGroupCoverages function and addReproduciblePeakSet using MACS275. Initial clustering was performed using the addIterativeLSI and addClusters functions, and visualized using UMAP. Top markers for each cluster were calculated using getMarkerFeatures (using the GeneScoreMatrix) and significant markers were defined as markers with a false-discovery rate of <0.05 and Log2FC ≥ 1 or ≤ −1. To add imputation weights and smooth the signal across nearby cells for improved visual interpretation, the addImputeWeights function was used and data were visualized using the plotEmbedding function. Differentially accessible regions were calculated using the getMarkerFeatures using the PeakMatrix. Data were visualized using base R plotting functions or in-built ArchR functions, such as plotMarkers or plotBrowserTrack.

LPS-induced lung inflammation model

Acute lung injury was induced by intranasal instillation of lipopolysaccharide (LPS; Escherichia coli O111:B4, Sigma-Aldrich, L3012). Mice were deeply anaesthetised with inhaled isoflurane to achieve a reduced respiratory rate with augmented tidal breathing. LPS (60 μg in 50 μl sterile PBS) was delivered dropwise to the nares while the mice were held in an upright position. During deep inspiratory efforts, animals were gently rotated to alternate the orientation of the main bronchi and promote more uniform distribution of the inoculum.

Lung immune cell suspensions

Mice were euthanized 4 days after LPS administration. Bronchoalveolar lavage fluid and lung tissues were collected. Lung tissues were weighed before further processing. Dissected mouse lung was collected and finely minced in 1 ml of digestion buffer. Mouse lungs were incubated in 1 ml digestion buffer (RPMI-1640 medium with 2% FCS and 1× penicillin–streptomycin–glutamine solution (10378016, Roche) containing 0.2 mg ml−1 liberase (05401020001, Roche), 0.2 mg ml−1 DNase I (DN25-100MG, Sigma-Aldrich) and 0.5 mg ml−1 hyaluronidase (LS002592, Worthington). After 1 h incubation, the suspension was passed through a 40 µm mesh to remove undigested clumps and debris. The flow-through was centrifuged at 500 rcf for 5 min. The pellet was washed once in 5 ml RPMI, and the resultant isolated cells were stimulated with PMA and ionomycin in the presence of brefeldin A (Cell Activation Cocktail, BioLegend) for 1.5 h at 37 °C for subsequent cytokine staining and then prepared for FACS analysis.

Human psoriasis scRNA-seq analysis

Publicly available scRNA-seq datasets from psoriasis vulgaris lesions were obtained from EGA (EGAS00001007373 and EGAS00001005271; n = 15 samples) as reported previously76,77. Count matrices were loaded into R using Read10X (Seurat) and processed with Seurat78 to generate one Seurat object per sample. Putative doublets were identified and removed using scDblFinder79. Cells were filtered before downstream analysis to retain those with 100–6,000 detected genes, <20% mitochondrial transcripts and <50% ribosomal transcripts. Filtered datasets were merged and normalized in Seurat using standard workflows. Cell type labels were assigned by reference mapping to an annotated psoriasis immune atlas76 using FindTransferAnchors, TransferData, AddMetaData and MapQuery. Marker genes were identified using FindAllMarkers, and visualization was performed using FeaturePlot and VlnPlot.

FTY720 treatments

Mice received daily intraperitoneal injections of 100 µl per mouse of FTY720 (1 mg per kg) or water (vehicle), starting 1 day before the IMQ challenge and continuing daily through its duration. This treatment was applied during either the initial disease onset or the rechallenge phase.

Thick-section 3D confocal microscopy

Tissue processing for 3D confocal imaging: after CO2 euthanasia, the dorsal back skin was excised and floated dermis side down in 2% PFA (Thermo Fisher Scientific) for 1 h at 4 °C, then fully submerged in fresh 2% PFA for an additional 6 h at 4 °C. Tissue was subsequently cryoprotected in 30% sucrose overnight at 4 °C. One-centimetre-squared sections were embedded in OCT compound (Thermo Fisher Scientific), snap-frozen on dry ice and stored at −80 °C. Using a cryostat, 200-µm thick sections were cut, washed in PBS and blocked for 24 h at 37 °C in DPBS containing 0.3% Triton X-100, 1% host serum (matched to the secondary antibody) and 1% BSA. The sections were incubated with primary antibodies diluted in blocking buffer for 48–72 h at 37 °C, washed three times for 2 h each in PBS and incubated with appropriate secondary antibodies for 24 h at 37 °C. The sections were then washed three times for 8 h total and cleared using Ce3D clearing solution (40% n-methylacetamide) before imaging.

Imaging antibodies

Primary antibodies used for mouse imaging included rabbit anti-dsRed (Takara, 632496, 1:400), rat anti-CD49f–AF488 (BioLegend, 313608, 1:200), rat anti-α-smooth muscle actin–CF405S (Biotium, BNC040665, 1:100) and goat anti-FABP5 (R&D Systems, AF1476-SP, 1:400). Secondary antibodies conjugated to Alexa Fluor 555 or Alexa Fluor 594 (Thermo Fisher Scientific) were used as appropriate.

Confocal microscopy

Cleared thick sections were imaged using the Leica SP8 upright laser-scanning confocal microscope equipped with a 405 nm laser and tuneable white light laser, using a 20× water-immersion objective. z-Stacks were acquired under identical acquisition settings within experiments to allow qualitative comparison across conditions.

Full-thickness skin transplantation

Donor mice were anaesthetised with isoflurane. Anaesthesia depth was confirmed by toe pinch. The left dorsal back skin of the donor was shaved with an electric razor and disinfected with povidone-iodine and 70% alcohol. Using sterile scissors and aseptic technique, full-thickness left dorsal back skin was collected using blunt dissection at the level of the areolar connective tissue. After graft collection, the donor was euthanized by cervical dislocation. Under a dissecting microscope, connective tissue, fat and the panniculus carnosus were removed from the graft using fine scissors. Individual grafts measuring around 15 × 15 mm were cut and stored on sterile PBS-soaked gauze in a Petri dish on ice. A single donor yielded two grafts for two recipient mice.

Recipient mice were anaesthetised with isoflurane (induction at 3%, maintenance at 2%) and given bupivacaine (local) and Ethiqa XR (subcutaneous) for analgesia. The upper back (thoracic) region was shaved and disinfected with 10% povidone-iodine. A graft bed of matching size (15 mm square) was created by carefully excising skin while preserving the panniculus carnosus and its superficial vasculature. The donor graft was placed on the bed, aligned without folds and secured with eight interrupted sutures at the corners and midpoints of each edge. Once suturing was complete, the thorax was wrapped with an adhesive bandage. The bandage was adjusted to allow free breathing and thoracic excursion.

The recipient mice were returned to the housing facility after they could move freely. On postoperative day 7, the bandages were removed under brief anaesthesia by cutting only the ventral side of the dressing to avoid disturbing the graft. The grafts were inspected for signs of vascularization; contraction, scabbing or firmness indicated technical failure. For analgesia, Ethiqa XR was administered pre-operatively for sustained pain control. Additional analgesics were provided as required under veterinary guidance.

Statistics and reproducibility

Statistical analyses were performed with Prism (GraphPad, v.10 and v.11). P values were calculated using Welch’s t-tests unless otherwise noted. Statistical tests were two-sided. When applicable, mice were randomly assigned to treatment or control groups. Experimental data were not excluded from the statistical analyses, except for exclusions due to technical errors or loss of confidence in appropriate controls. Measurements were taken from distinct biological samples, except for ear thickness, which was measured longitudinally in the same mice at multiple time points. The investigators were not blinded in the studies unless otherwise stated. No estimate of variance was made between each group. All in vivo experiments were conducted with at least two independent cohorts unless otherwise specified. Unless otherwise noted, data from one instance of the repeated experiments are represented in this Article. The recurrence experiment in which mice were allowed to recover for 6.5 months before rechallenge with IMQ was only conducted once. The targeted lipidomics analyses were conducted once. Bulk RNA-seq, scRNA-seq and snATAC–seq experiments were conducted once using multiple biological samples per group (as indicated in the figure legends). Histological analyses were performed on tissues from a single experimental cohort for each comparison. Unless otherwise indicated, at least five mice per group were examined; for each mouse, three serial sections were assessed at each of at least two separately cut tissue levels. Thick-section confocal imaging was performed once using two mice per group, with three 200 µm sections imaged per mouse.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The raw and processed bulk RNA-seq data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under BioProject accession number PRJNA1212208. The raw and processed scRNA-seq and snATAC–seq data generated in this study have been deposited in the Gene Expression Omnibus (GEO) repository under accession number GSE287431. Publicly available human psoriasis scRNA-seq datasets analysed in this study are available from the European Genome-phenome Archive (EGA) under accessions EGAS00001007373 and EGAS00001005271. Sequencing reads were aligned to the UCSC mm10 or GRCm39 (RefSeq: GCF_000001635.27) mouse reference genome assemblies, as described in the Methods. Cell type annotation was performed using the PanglaoDB database and the OmniPath resource accessed through decoupler. Source data are provided with this paper.

Code availability

Code used in this manuscript has been deposited at GitHub (https://github.com/bapatlab/RNAseq_scRNAseq_snATACseq).

References

  1. Kotas, M. E. & Medzhitov, R. Homeostasis, inflammation, and disease susceptibility. Cell 160, 816–827 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 13, 633–643 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. Yosipovitch, G., DeVore, A. & Dawn, A. Obesity and the skin: skin physiology and skin manifestations of obesity. J. Am. Acad. Dermatol. 56, 901–916 (2007).

    Article  PubMed  Google Scholar 

  5. Cox, A. J., West, N. P. & Cripps, A. W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 3, 207–215 (2015).

    Article  CAS  PubMed  Google Scholar 

  6. Bapat, S. P. et al. Obesity alters pathology and treatment response in inflammatory disease. Nature 604, 337–342 (2022).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jiang, Z., Tabuchi, C., Gayer, S. & Bapat, S. P. Immune dysregulation in obesity. Ann. Rev. Pathol. Mech. Dis. (2025).

  8. Swanson, K. V., Deng, M. & Ting, J. P.-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lee, Y. et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991–999 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576–587 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Naik, S. & Fuchs, E. Inflammatory memory and tissue adaptation in sickness and in health. Nature 607, 249–255 (2022).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dyck, L. & Lynch, L. Diverse effects of obesity on antitumor immunity and immunotherapy. Trends Mol. Med. https://doi.org/10.1016/j.molmed.2022.11.004 (2022).

  13. Falagas, M. E. & Kompoti, M. Obesity and infection. Lancet Infect. Dis. 6, 438–446 (2006).

    Article  PubMed  Google Scholar 

  14. Pugliese, G. et al. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. Int. J. Obesity 46, 449–465 (2022).

    Article  CAS  Google Scholar 

  15. Jensen, P. & Skov, L. Psoriasis and obesity. Dermatology 232, 633–639 (2017).

    Article  Google Scholar 

  16. Peters, U., Dixon, A. E. & Forno, E. Obesity and asthma. J. Allergy Clin. Immunol. 141, 1169–1179 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bader, J. E. et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature 630, 968–975 (2024).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sivasami, P. et al. Obesity-induced dysregulation of skin-resident PPARγ+ Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 56, 1844–1861 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kanda, N., Hoashi, T. & Saeki, H. Nutrition and psoriasis. Int. J. Mol. Sci. 21, 5405 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Phan, C. et al. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé Cohort. JAMA Dermatol. 154, 1017 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  21. Constantin, C., Surcel, M., Munteanu, A. & Neagu, M. Insights into nutritional strategies in psoriasis. Nutrients 15, 3528 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fits, L. vander et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836–5845 (2009).

    Article  PubMed  Google Scholar 

  23. Shi, Z. et al. Short-term exposure to a western diet induces psoriasiform dermatitis by promoting accumulation of IL-17A-producing γδ T cells. J. Invest. Dermatol. 140, 1815–1823 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang, Y. et al. Epidermal fatty acid binding protein promotes skin inflammation induced by high-fat diet. Immunity 42, 953–964 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pantelyushin, S. et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 2252–2256 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wright, H. L., Moots, R. J., Bucknall, R. C. & Edwards, S. W. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 49, 1618–1631 (2010).

    Article  CAS  PubMed  Google Scholar 

  27. Bando, J. K. & Colonna, M. Innate lymphoid cell function in the context of adaptive immunity. Nat. Immunol. 17, 783–789 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mendoza, A. et al. Enkephalin-producing regulatory T cells in the skin restrain local inflammation through control of nociception. Sci. Immunol. 10, eadz6869 (2025).

  29. Saravia, J., Chapman, N. M. & Chi, H. Helper T cell differentiation. Cell. Mol. Immunol. 16, 634–643 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331–341 (2009).

    Article  CAS  PubMed  Google Scholar 

  31. Gaublomme, J. T. et al. Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. Cell 163, 1400–1412 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Mantovani, A., Dinarello, C. A., Molgora, M. & Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50, 778–795 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhou, L. & Littman, D. R. Transcriptional regulatory networks in Th17 cell differentiation. Curr. Opin. Immunol. 21, 146–152 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ciofani, M. et al. A validated regulatory network for Th17 cell specification. Cell 151, 289–303 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Boraschi, D., Italiani, P., Weil, S. & Martin, M. U. The family of the interleukin-1 receptors. Immunol. Rev. 281, 197–232 (2018).

    Article  CAS  PubMed  Google Scholar 

  36. Rendon, A. & Schäkel, K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20, 1475 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Iijima, N. & Iwasaki, A. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346, 93–98 (2014).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vesely, M. C. A. et al. Effector TH17 cells give rise to long-lived TRM cells that are essential for an immediate response against bacterial infection. Cell 178, 1176–1188 (2019).

    Article  Google Scholar 

  39. Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Ann. Rev. Immunol. 30, 69–94 (2012).

    Article  CAS  Google Scholar 

  40. Künzli, M. & Masopust, D. CD4+ T cell memory. Nat. Immunol. 24, 903–914 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  41. Liu, Z. et al. Glucocorticoid signaling and regulatory T cells cooperate to maintain the hair-follicle stem-cell niche. Nat. Immunol. 23, 1086–1097 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ali, N. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 169, 1119–1129 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kiuchi, M. et al. Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4+ T cells. Science 390, eadp0714 (2025).

    Article  CAS  PubMed  Google Scholar 

  44. Ciancio, G. et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Front. Immunol. 17, 1744308 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lebwohl, M. et al. Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity. JAMA Dermatol. 162, 709–719 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  46. Buonanno, S. et al. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflamm. Res. 74, 167 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Petković-Dabić, J. et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules 15, 46 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  48. Higashi, Y. et al. High-fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice. Exp. Dermatol. 27, 178–184 (2018).

    Article  CAS  PubMed  Google Scholar 

  49. Nakamizo, S. et al. High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing γδ T cells. Sci. Rep. 7, 14076 (2017).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  50. Shi, Z. et al. Short-term western diet intake promotes IL-23-mediated skin and joint inflammation accompanied by changes to the gut microbiota in mice. J. Invest. Dermatol. 141, 1780–1791 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gerriets, V. A. et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur. J. Immunol. 46, 1970–1983 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Elgazar-Carmon, V., Rudich, A., Hadad, N. & Levy, R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 49, 1894–1903 (2008).

    Article  CAS  PubMed  Google Scholar 

  53. Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407–1412 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Son, S. et al. Neutrophils preserve energy storage in sympathetically activated adipocytes. Nature 650, 718–726 (2026).

    Article  ADS  CAS  PubMed  Google Scholar 

  55. Yu, J. et al. FABP5 in skin macrophages mediates saturated fat-induced IL-1β signaling in psoriatic inflammation. Cell Rep. 44, 116254 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Shen, F. W. et al. Cloning of Ly-5 cDNA. Proc. Natl Acad. Sci. USA 82, 7360–7363 (1985).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  57. Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).

    Article  ADS  CAS  PubMed  Google Scholar 

  58. Mombaerts, P. et al. Mutations in T-cell antigen receptor genes α and β block thymocyte development at different stages. Nature 360, 225–231 (1992).

    Article  ADS  CAS  PubMed  Google Scholar 

  59. Madsen, L. et al. Mice lacking all conventional MHC class II genes. Proc. Natl Acad. Sci. USA 96, 10338–10343 (1999).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  60. Koller, B. H., Marrack, P., Kappler, J. W. & Smithies, O. Normal development of mice deficient in β2M, MHC class I proteins, and CD8+ T Cells. Science 248, 1227–1230 (1990).

    Article  ADS  CAS  PubMed  Google Scholar 

  61. Itohara, S. et al. T cell receptor δ gene mutant mice: independent generation of αβ T cells and programmed rearrangements of γδ TCR genes. Cell 72, 337–348 (1993).

    Article  CAS  PubMed  Google Scholar 

  62. Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15, 763–774 (2001).

    Article  CAS  PubMed  Google Scholar 

  63. Kovarova, M. et al. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J. Immunol. 189, 2006–2016 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Robson, M. J. et al. Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1. PLoS ONE 11, e0150068 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  65. Aghajani, K., Keerthivasan, S., Yu, Y. & Gounari, F. Generation of CD4creERT2 transgenic mice to study development of peripheral CD4-T-cells. Genesis 50, 908–913 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).

    Article  CAS  PubMed  Google Scholar 

  67. Clark, I. C. et al. Microfluidics-free single-cell genomics with templated emulsification. Nat. Biotechnol. 41, 1557–1566 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 https://doi.org/10.1186/s13059-017-1382-0 (2018)

  69. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  70. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  71. Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  72. Franzén, O., Gan, L.-M. & Björkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database 2019, baz046 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  73. Türei, D., Korcsmáros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. Nat. Methods 13, 966–967 (2016).

    Article  PubMed  Google Scholar 

  74. Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet. 53, 403–411 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zhang, Y. et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  76. Liu, Y. et al. Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci. Immunol. 7, eabl9165 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Wu, D. et al. A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response. Sci. Immunol. 9, eadi2848 (2024).

    Article  CAS  PubMed  Google Scholar 

  78. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Germain, P.-L., Lun, A., Meixide, C. G., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res. 10, 979 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank R. Ricardo-Gonzalez, P. Dumesic and J. Cyster for advice and reading the manuscript; T. Hoffmann for consultation relating to statistical analyses; E. Vidal (DrawImpacts) for scientific graphic illustration; the staff at Life Science Editors for editing services; the staff at UCSF Parnassus Flow CoLab (RRID: SCR_018206), which is partly supported by the DRC Center Grant NIH P30 DK063720, for enabling use of instruments and services related to flow cytometry; and T. Scharschmidt for sharing the Cd4creERT2Ai14 and Il1r1fl/fl mice.

Funding

Z.J. was supported by the UCSF Biomedical Sciences graduate program, UCSF Diabetes Center Klein Fellowship and George Coleman Discovery Fellowship; E.D.M. by the Dermatology Foundation Career Development Award and the Grunfeld Scholar Award San Francisco VAMC; L.Q. and D.Z. by the Nina Ireland Program for Lung Health; J.B.C. by a Merit Review Award from the Veterans Health Administration Office of Research and Development (I01CX002608) and the LEO foundation (LF-OC-22-001029); and K.J.S. by R01DK125260, P30DK116074, DK142416 and the American Heart Association 23IPA1042031. This research was supported in part by Arc Institute. K.J.S. is an Arc Institute Innovation Investigator and a Weill Cancer Hub West Investigator. M.R.L. was supported by NIH R35HL161241; A.B.M. by NIH R01AR084863; and M.A.M. by NIH R35HL177135. S.P.B. is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists, serves as a Weill Cancer Hub West Investigator and is an awardee of the American Diabetes Association Pathway to Stop Diabetes program; he has been supported by US National Institutes of Health grants R38 HL143581 and K38 HL154202, as well as by the Larry L. Hillblom Foundation, Parker B. Francis Foundation, Baszucki Lymphoma Therapeutic Initiative, Parker Institute for Cancer Immunotherapy, Benioff Center for Microbiome Medicine, UCSF Nutrition Obesity Research Center and the American Partnership for Eosinophilic Disorders.

Author information

Author notes

  1. These authors contributed equally: Zewen Jiang, John M. Tayeri

Authors and Affiliations

  1. Department of Pathology, University of California, San Francisco, CA, USA

    Zewen Jiang, John M. Tayeri, Joy Li, Vrinda Johri, Megan E. Dobson, Sarah G. Gayer, Arum Yoo, Nandini U. Borkar, Shin Shyan Chuah, Preetal Deshpande, Brittany Davidson, Jessica Tsui, Nicholas F. Kuhn, Tristan Courau, Alexis J. Combes & Sagar P. Bapat

  2. ImmunoX Initiative, University of California, San Francisco, CA, USA

    Zewen Jiang, John M. Tayeri, Im-Hong Sun, Joy Li, Vrinda Johri, Megan E. Dobson, Chihiro Tabuchi, Sarah G. Gayer, Arum Yoo, Nandini U. Borkar, Jiaxi Wang, Han Yin, Shin Shyan Chuah, Preetal Deshpande, Brittany Davidson, Jessica Tsui, Nicholas F. Kuhn, Tristan Courau, Mark R. Looney, Alexis J. Combes, Ari B. Molofsky, James M. Gardner & Sagar P. Bapat

  3. Department of Surgery, University of California, San Francisco, CA, USA

    Im-Hong Sun, Jiaxi Wang, Han Yin, Vinh Q. Nguyen & James M. Gardner

  4. Diabetes Center, University of California, San Francisco, CA, USA

    Im-Hong Sun & James M. Gardner

  5. Department of Dermatology, University of California, San Francisco, CA, USA

    E. Dean Merrill, Margaret M. Lowe, Raymond J. Cho, Jeffrey B. Cheng & Michael D. Rosenblum

  6. Department of Medicine, University of California, San Francisco, CA, USA

    Longhui Qiu, Dongliang Zhang, Ruriko Watanabe, Mazharul Maishan, Mark R. Looney, Alexis J. Combes & Michael A. Matthay

  7. UCSF CoLabs, University of California, San Francisco, CA, USA

    Vrinda Johri, Brittany Davidson, Jessica Tsui & Alexis J. Combes

  8. Department of Microbiology and Immunology, University of California, San Francisco, CA, USA

    Chihiro Tabuchi

  9. Curio Science, Brisbane, Queensland, Australia

    Sophie Curio

  10. Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

    Abdullah El Kurdi

  11. Dermatology Service, San Francisco Veterans Administration Health Care System, San Francisco, CA, USA

    Jeffrey B. Cheng

  12. Department of Pathology, Stanford University, Stanford, CA, USA

    Katrin J. Svensson

  13. Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA, USA

    Katrin J. Svensson

  14. Arc Institute, Palo Alto, CA, USA

    Katrin J. Svensson

  15. Weill Cancer Hub West, Stanford University and University of California, San Francisco, CA, USA

    Katrin J. Svensson, Ari B. Molofsky & Sagar P. Bapat

  16. Department of Laboratory Medicine, University of California, San Francisco, CA, USA

    Mark R. Looney

  17. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA

    James M. Gardner

Authors

  1. Zewen Jiang
  2. John M. Tayeri
  3. Im-Hong Sun
  4. Joy Li
  5. E. Dean Merrill
  6. Longhui Qiu
  7. Dongliang Zhang
  8. Vrinda Johri
  9. Megan E. Dobson
  10. Ruriko Watanabe
  11. Mazharul Maishan
  12. Margaret M. Lowe
  13. Chihiro Tabuchi
  14. Sarah G. Gayer
  15. Arum Yoo
  16. Nandini U. Borkar
  17. Jiaxi Wang
  18. Han Yin
  19. Shin Shyan Chuah
  20. Preetal Deshpande
  21. Brittany Davidson
  22. Jessica Tsui
  23. Nicholas F. Kuhn
  24. Tristan Courau
  25. Sophie Curio
  26. Vinh Q. Nguyen
  27. Abdullah El Kurdi
  28. Raymond J. Cho
  29. Jeffrey B. Cheng
  30. Katrin J. Svensson
  31. Michael D. Rosenblum
  32. Mark R. Looney
  33. Alexis J. Combes
  34. Ari B. Molofsky
  35. Michael A. Matthay
  36. James M. Gardner
  37. Sagar P. Bapat

Contributions

Z.J., J.M.T. and S.P.B. designed and conceived the research. S.P.B., R.J.C., J.B.C., K.J.S., M.D.R., M.R.L., A.J.C., A.B.M., M.A.M. and J.M.G. supervised the research. Z.J., J.M.T., I.-H.S., J.L., E.D.M., L.Q., D.Z., M.E.D., V.J., R.W., M.M., M.M.L., C.T., S.G.G., A.Y., N.B., J.W., S.S.C., P.D., B.D., J.T. and V.Q.N. performed experiments. Z.J., J.M.T., E.D.M., H.Y., N.F.K., T.C., S.C., A.E.K., R.J.C., J.B.C., A.J.C., M.M. and S.P.B. analysed data. Z.J., J.M.T. and S.P.B. wrote the manuscript.

Corresponding author

Correspondence to Sagar P. Bapat.

Ethics declarations

Competing interests

J.B.C. and R.J.C. received grants from BMS, Janssen, Regeneron, Sanofi and Sun Pharma outside the submitted work. K.J.S. is a co-founder and equity holder of Merrifield Therapeutics and has equity in American Bioenhancement. K.J.S. has received research funds from Merck, Eli Lilly and Pfizer, and consulting fees from AbbVie, Novo Nordisk and American Bioenhancement. The Combes laboratory receives research support from Eli Lilly and Genentech for work unrelated to this Article. A.J.C. is a member of the scientific advisory board of Foundery Innovations and has received consulting fees from Survey Genomics. S.P.B. has received an honorarium from Amgen for a scientific seminar.

Peer review

Peer review information

Nature thanks Maziar Divangahi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data figures and tables

Extended Data Fig. 1 Inflammatory profiling of short- and long-term high-fat diet-fed mice, and associated flow cytometry gating strategies.

a, Serum measurements of inflammatory cytokines (n = 4 LFD and n = 5 for 1 week and 10 weeks of HFD). b, Conventional T cells (Tconv) are defined as CD45+ CD3εInt CD4+ FOXP3−; regulatory T (Treg) cells are defined as CD45+ CD3εInt CD4+ FOXP3+; TH17 cells are defined as Tconv cells expressing RORγt, with competency for IL-17A, IL-17F, and IL-22 assessed separately; γδ T cells are defined as CD45+ CD3εInt γδTCR+; and neutrophils are defined as CD45+ CD3ε− CD11b+ Ly6G+. c,d, Quantification of TH17 cells (c) and γδ T cells (d) in skin of one ear (n = 10 per group). Data are mean ± s.e.m. Kruskal–Wallis tests were used in (a) with Dunn’s correction for multiple comparisons for each cytokine. No cytokines remained significant after Benjamini–Hochberg correction across the 18 cytokines. Brown–Forsythe and Welch ANOVA tests were performed, followed by Dunnett’s T3 multiple comparisons test to calculate P values in (c,d). **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 2 Prolonged HFD impairs glucose tolerance, and inflammatory amplification depends on the timing of fat, not glucose, exposure relative to disease onset.

a,b, Glucose tolerance test tracings (a) and area under the curve measurements (b) in mice fed LFD or HFD for 1 or 10 weeks. c,d, Change in ear thickness (c) and frequency of TH17 cells (d) in mice fed diets containing 10, 30, 45, or 60 kcal% fat. e, Change in ear thickness in mice fed LFD or MFD (45 kcal% fat) (left panel) or control diet (CD) or Western diet (WD; 40 kcal% fat, 29 kcal% sucrose) (right panel). f,g, Ear thickness in mice fed CD or WD (f), or LFD or HFD (g), in the absence of imiquimod (IMQ) challenge.h,i, Experimental schematic (h) and change in ear thickness (i) in mice given control or 15% glucose water at the indicated time. j,k, Experimental schematic (j) and change in ear thickness (k) in mice maintained on LFD or subjected to HFDin feeding. l-o, Schematic and change in ear thickness depicting HFD feeding outside of the disease-onset window (l), LFD feeding outside the disease-onset window (m), HFD feeding for 1 week, switched to LFD at IMQ initiation (n), WT or ob/ob mice switched from LFD to HFD at the indicated time (o). Data are mean ± s.e.m. n = 10 (a,b,g,m,n); n = 5 (c-f,i,k,l,o); Ordinary one-way ANOVA was used, followed by Tukey’s multiple-comparisons test (b). Two-sided unpaired Welch’s t-test was used (e-g,i,k,o), and P values were corrected using Holm–Šídák method (f,g). Brown–Forsythe and Welch ANOVA tests were performed followed by Dunnett’s T3 multiple comparisons test (c,d,l-n). Peak values were tested in (c,e,i,k,l-o). *P < 0.05, **P < 0.01, ***P < 0.001. The diagrams in h, j,and l–o were created using BioRender; Jiang, Z. https://BioRender.com/djzqs4a (h), https://BioRender.com/luxb5f2 (j and o), https://BioRender.com/ol12zv6 (l), https://BioRender.com/j5i0pyr (m), https://BioRender.com/03mh8zp (n) (2026).

Source data

Extended Data Fig. 3 Semaglutide improves systemic metabolic parameters but does not broadly alter baseline inflammation or attenuate IMQ-induced inflammation during short-term HFD feeding.

a,b, GTT (a) and AUC in mice fed LFD or HFD and administered vehicle or semaglutide (b). c, Body weight of mice over a 7-day period after initiating daily injections of vehicle or semaglutide. d, Body weights taken on day 7. e, Serum concentrations in mice treated as in (a) for insulin and leptin. f, Serum GLP-1 immunoreactivity in mice treated as in (a). This assay recognizes semaglutide, confirming drug exposure in semaglutide-treated mice. g, Total weights of inguinal (iWAT) and gonadal (gWAT) white adipose tissue from mice fed LFD or HFD and administered vehicle or semaglutide for a 7-day period. h, Visualization of iWAT and gWAT. i, Serum cytokine and chemokine concentrations measured in mice treated as in (a). j, Representative gross images of ears from mice treated as in (a) without IMQ challenge. k, Flow cytometric quantification of indicated splenic conventional CD4+ Tconv cells. l, Representative gross images of spleens from mice treated as in (a). m, Experimental schematic for mice in (n-p). n, Representative gross images of ears after IMQ treatment. o, Change in ear thickness. p, Flow cytometric quantification of TH17 cells after IMQ treatment. q, Flow cytometric quantification of neutrophils before IMQ challenge. n = 5 (a,b,k,p); n = 10 (c-g,i,o); n = 6 (q). Data are mean ± s.e.m. Ordinary one-way ANOVA was used, followed by Tukey’s multiple-comparisons test (b). Brown–Forsythe and Welch one-way ANOVA followed by Dunnett’s T3 multiple-comparisons test were performed (c-g,k,o,p). Only last-day values were used (c,o). Kruskal–Wallis tests were used in (i) with Dunn’s correction for multiple comparisons for each cytokine. No cytokines remained significant after Benjamini–Hochberg correction across the 18 cytokines. Two-sided unpaired Welch’s t-test was used to calculate P value in (q). *P < 0.05, **P < 0.01, ***P < 0.001. The diagram in m was created using BioRender; Jiang, Z. https://BioRender.com/ax6z6ja (2026).

Source data

Extended Data Fig. 4 Short-term high-fat diet during disease onset amplifies type 17 inflammatory responses.

a, Representative flow cytometry plots of IL-17A+, IL-17F+, IL-22+, and RORγt+ Tconv cells in lesional skin. b, Quantification of (a). c,d, Frequency (c) and total number (d) of IL-17A+, IL-17F+, IL-22+, and RORγt+ Tconv cells in skin-draining lymph nodes. e, Frequency of TH22 cells (IL-17A− IL-22+ FOXP3− CD4+ T cells) in skin as percentage of Tconv cells. f, Frequency of Ki-67+ Tconv cells in skin. g, Frequency of Treg cells as a percentage of CD4+ T cells in skin. h, Total number of neutrophils in skin. i,j, Frequency (i) and total number (j) of IL-17A+, IL-17F+, IL-22+, and RORγt+ γδ T cells in skin. k, Representative gross ear images of mice fed LFD, HFDin, or HFD on day 6 of IMQ treatment. l, Frequency of IL-17A+, IL-17F+, IL-22+, and RORγt+ Tconv cells in skin in LFD, HFDin, and HFD cohorts. Data are shown as mean ± s.e.m. n = 5 for LFD and 1-week HFD and n = 10 for 10 weeks HFD for (b-g,i,j); n = 5 for (h); n = 10 for (l). Brown–Forsythe and Welch ANOVA tests were performed followed by Dunnett’s T3 multiple-comparison test to calculate P values for (b–j,l). #P = 0.07, *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 5 CD4+ T cell depletion eliminates diet-associated inflammatory differences and scRNA-seq identifies skin immune cell populations.

a,b, Change in ear thickness (a) and total number of lesional CD4+ T cells (b) in mice treated with IgG isotype control or anti-CD4 antibody and challenged with IMQ. c, Representative ear images of mice on day 6 of IMQ treatment following either IgG or anti-CD4 antibody treatment. d, Representative hematoxylin and eosin (H&E) ear histology of mice on day 6 of IMQ treatment upon either IgG or anti-CD4 antibody treatment. e, Total number of lesional γδ T cells in mice treated with IgG isotype control or anti-CD4 antibody and challenged with IMQ. f, Dot plot of selected marker genes across CD4+ T cell clusters identified by scRNA-seq. Dot size indicates the fraction of cells expressing each gene, and colour intensity reflects mean expression within each cluster. g, Dot plot of selected marker genes across immune cell clusters identified by scRNA-seq from lesional CD45+ cells of LFD- or HFD-fed mice after IMQ challenge. Dot size indicates the fraction of cells expressing each gene, with darkness of the shade representing mean expression within each cluster. Scale bars, 100 μm. n = 10 (a); n = 6 except n = 4 for HFD anti-CD4 antibody treatment (b,e); n = 1 pooled sample from 10 mice per group (f,g). Data are mean ± s.e.m. Two-sided unpaired Welch’s t-tests were used to calculate P values. Only peak values were tested in (a). *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 6 Short-term HFD feeding promotes psoriatic inflammation via IL-1R1+ CD4+ T cells.

a-d, Frequency of CD4+ T cells across assigned clusters (a), Il17a, Il17f, Il22, Il23r, and Rorc expression of CD4+ T cells from the TH17 clusters (b), TH17 pathogenicity score of CD4+ T cells in the TH17 clusters (c), and differential gene analysis in the TH17 clusters (d) as per clustering of scRNA-seq data in Fig. 2l. e, Representative histogram of IL-1R1 expression and quantification by mean fluorescence intensity (MFI) of RORγt+ FOXP3− CD4+ T (TH17) cells from lesional skin. f,g, Il17a, Il17f, Il22, Il23r, and Rorc expression (f) and TH17 pathogenicity score (g) of Il1r1− and Il1r1+ TH17 cells as per clustering of scRNA-seq data in Fig. 2l. h, Representative ear images of Cd4Cre or Cd4Cre Il1r1fl/fl mice fed with either LFD or HFD on day 6 of IMQ treatment. i, TH22 cells as a percentage of Tconv cells in skin after IMQ challenge. n = 9 for LFD and n = 8 for HFD (e). n = 5 for all groups except HFD, Cd4Cre Il1r1fl/fl which was n = 7 in (i). n = 1 (pooled from 10 mice per group) for scRNA-seq (b,c,f,g). Data are mean ± s.e.m. Two-sided Welch’s t-test was used to calculate P values for (e) and two-sided Wilcoxon test was used to calculate P values for (b,c,f,g). P values were corrected for multiple comparisons using the Benjamini–Hochberg method (b,d,f). In (d), dashed lines indicate adjusted P = 10−4 and |log2 fold change | = 1. Panel i was analysed using two-way ANOVA followed by Šídák’s multiple comparisons test. The violin plots are presented as the internal box plot shows the median (center), interquartile range (25th–75th percentiles; box) and whiskers extending to the most extreme values within 1.5× the interquartile range (c,g). *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 7 HFD-amplified disease severity is dependent on NLRP3.

a, Volcano plot of bulk-RNA-seq of IMQ-treated ears of LFD or HFD-fed mice. b, Normalized counts of Il1a, Il1b, and Nlrp3. c-e, Change in ear thickness over time (c), frequency of RORγt+ TH17 cells (d), total number of neutrophils in the skin (e) from WT or Nlrp3−/− mice fed control diet (CD) or Western diet (WD) and challenged with IMQ. f,g, Glucose tolerance test tracings (f) and area under curve measurements (g) of WT and Nlrp3−/− mice fed LFD or HFD for 1 week. h-k, Change in ear thickness over time (h), representative ear images (i), total number of IL-17A+, IL-17F+, IL-22+, and RORγt+ skin Tconv (j) and skin neutrophils (k) of WT mice fed on HFD treated with vehicle or MCC950 with IMQ treatment. l, Normalized counts of Il1b and Nlrp3 in ear skin of LFD or HFD-fed mice before IMQ challenge. n = 5 (a,b), n = 10 (c-h,j,k) except n = 9 for Nlrp3−/− mice fed WD where applicable, and n = 4 (l). m, UMAP visualization of integrated scRNA-seq data from psoriasis vulgaris lesions (EGA: EGAS00001007373 and EGAS00001005271; n = 15 samples). n, Feature plots showing NLRP3 (left) and IL1B (right) expression. o, Violin plots showing distributions of NLRP3 (left) and IL1B (right) expression across cells within the Mono, LC2, and moDC3 clusters for each psoriasis vulgaris sample (PV1–PV15); points denote individual cells. Data are mean ± s.e.m. DESeq2 Wald test was used to calculate P values and P values were corrected for multiple comparisons using the Benjamini–Hochberg method (a,b,l). Two-way ANOVA followed by Šídák’s multiple comparisons test was used (d,e,g). Otherwise, two-sided Welch’s t-test was used to calculate P values. Only peak values were tested in (c,h). *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 8 Short-term high-fat diet amplifies lung TH17 inflammation through neutrophil-dependent, T cell–intrinsic IL-1R1 signalling.

a, Total lung neutrophil counts in LFD- or HFD-fed mice given intranasal PBS (baseline, pre-LPS). b, Change in lung weight 4 days after LPS challenge in LFD- and HFD-fed mice. Change in lung weight reflects lung weight 4 days after LPS challenge normalized to the mean of PBS-treated controls within each diet group. c, Total lung RORγt+ TH17 cells 4 days after LPS challenge. d, Frequency of RORγt+ TH17 cells among lung CD4+ Tconv cells after LPS challenge. e, Frequency of IL-17A+ lung CD4+ Tconv cells in LFD- or HFD-fed mice treated with isotype control IgG or anti-Ly6G (neutrophil depletion) during LPS challenge. f, Frequency of IL-17A+ cells among lung CD4+ Tconv in Cd4Cre and Cd4Cre Il1r1fl/fl mice fed LFD or HFD and challenged with LPS. n = 5 (a,e); n = 9 (b-d); n = 4 LFD (both genotypes) and n = 5 HFD (both genotypes) (f). Data are mean ± s.e.m. Two-way ANOVA followed by Šídák’s multiple comparisons test was used (e,f). Otherwise, two-sided Welch’s t-test was used to calculate P values (a-d). *P < 0.05, **P < 0.01, ***P < 0.001.

Source data

Extended Data Fig. 9 Dietary state during priming, but not diet alone, establishes localized inflammatory memory requiring NLRP3 and CD4+ T cells.

a,b, Heatmap of selected inflammatory and immune-associated genes (a) and principal component analysis (PCA) (b) from bulk RNA-seq of recovered ear skin. c,d, Serum cytokines (c) and chemokines (d) after recovery. e, Change in ear thickness during secondary IMQ challenge after a 6.5-month recovery period. f, Change in ear thickness in mice fed HFD or LFD for one week, then LFD for two weeks, and challenged with IMQ on LFD. g, Secondary IMQ challenge applied to the previously inflamed (left) ear (left panel) or the contralateral previously unchallenged (right) ear (right panel) in LFD and HFDDODO cohorts. h-j, Mice fed HFD for 0, 1, or 12 weeks through disease onset, then maintained on LFD through the second challenge: longitudinal ear thickness (h), peak of onset (i), and peak of 2nd flare (j). k,l, Ear thickness during recurrence (k) and peripheral blood CD4+ and CD8+ T cell numbers (l) in mice treated with vehicle or FTY720. m, Gating strategy for resident memory CD4+ T cells (TRM). n, Ear thickness during recurrence in mice treated with MCC950 at disease onset (MCC950Onset) or at recurrence (MCC9502nd). n = 5 per group, except n = 4 for HFDDODO (c,d), n = 10 LFD and n = 9 HFDDODO (e), n = 8 for mice previously fed HFD for 1 week (f), n = 10 for the left-ear group (g), and n = 4 for HFD-Vehicle (k). Data are mean ± s.e.m. Two-sided Welch’s t-test was used to calculate P values in (e,f,g,k,l,n), with only peak values tested in (e,f,g,k,n) and correction by the Holm–Šídák method in (l). Brown–Forsythe and Welch ANOVA tests followed by Dunnett’s T3 multiple-comparison test were used for (i,j). Two-sided Mann–Whitney tests were used with Holm–Šídák correction and no data remained significant after correction (c,d). *P < 0.05, **P < 0.01, ***P < 0.001. The diagrams in f, g and k and n were created using BioRender; Jiang, Z. https://BioRender.com/1lb1zog (f), https://BioRender.com/vg8n5xp (g), https://BioRender.com/zo6nry9 (k), https://BioRender.com/gadqko8 (n) (2026).

Source data

Extended Data Fig. 10 Analysis of snATAC-seq of recovered skin CD4+ T cells and acute HFD-induced lipid remodelling.

a, UMAP visualization of single-nucleus ATAC-seq profiles from sorted CD4+ T cells of recovered skin, coloured by gene activity scores for TRM marker genes. b,c, Selected genome browser tracks of loci showing increased (b) and decreased (c) chromatin accessibility in Cluster 8 (C8) compared with all other clusters. Promoter regions are highlighted in green; putative regulatory elements are highlighted in yellow. d, Graphical abstract and model describing how short-term dietary changes can substantially and durably modify inflammatory disease trajectory. e, Targeted lipidomic profiling of ear skin from mice fed low-fat diet (LFD) or high-fat diet (HFD) for 7 days at baseline, showing omega-6 PUFA substrate abundance, oxidized linoleic acid metabolites, COX/prostanoid mediators, 5-LOX neutrophil-associated mediators, and 12/15-LOX inflammatory lipids. f, Heatmap showing relative expression of selected lipid handling and lipid remodelling genes significantly enriched in ear skin from HFD-fed mice by bulk RNA-seq analysis at baseline. Data are shown as mean ± s.e.m. n = 1 (pooled from 20 mice per group) for snATAC-seq (a-c); n = 10 per group for (e), except LFD TxB2 (n = 8 detected values; two samples were not detected); n = 4 per group for (f). Two-sided unpaired Welch’s t-tests were performed to calculate P values in (e). Differential gene expression analysis in (f) was performed using DESeq2 Wald tests with Benjamini–Hochberg false discovery rate correction across all genes. *P < 0.05, **P < 0.01, ***P < 0.001. The diagram in d was reproduced with permission from Emma Vidal, DrawImpacts.

Source data

Supplementary information

Supplementary Table 1 (download XLSX )

Differential gene expression in skin TH17 cells from HFD- versus LFD-fed mice after IMQ challenge. scRNA-seq differential expression results for the TH17 cluster of lesional CD4+ T cells isolated from mice fed the HFD or LFD for 1 week and challenged with IMQ. Columns report rank, gene symbol, log-transformed fold change (HFD versus LFD), nominal P values, Benjamini–Hochberg adjusted P values, Wilcoxon rank-sum test score and −log10-transformed adjusted P values. Related to Fig. 2l and Extended Data Fig. 6d.

Reporting Summary (download PDF )

Supplementary Table 2 (download XLSX )

Differential gene expression in whole ear tissue from HFD- versus LFD-fed mice at day 6 after IMQ challenge. Bulk RNA-seq differential expression results (DESeq2) for whole ear tissue from mice fed LFD or HFD and subsequently challenged with IMQ, analysed at day 6. The columns report Ensembl gene identifier, base mean expression, log2-transformed fold change, log2-transformed fold change in standard error, Wald statistic, nominal P values, Benjamini–Hochberg adjusted P values and gene symbols. Related to Fig. 3a and Extended Data Fig. 7a.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Z., Tayeri, J.M., Sun, IH. et al. Diet at disease onset determines tissue inflammatory memory. Nature (2026). https://doi.org/10.1038/s41586-026-11181-4

Download citation

  • Received: 11 February 2025

  • Accepted: 17 September 2026

  • Published: 28 October 2026

  • Version of record: 28 October 2026

  • DOI: https://doi.org/10.1038/s41586-026-11181-4

来源:Nature 综合主刊 · nature.com